Why the study?
Commercial APOE genotyping platforms are widely used in cardiovascular genetic studies, but their performance in genetically understudied populations such as Libyan patients with coronary heart disease is rarely verified.
Population
Libyan patients with coronary heart disease (60 patients total, with a validation subset of 28 individuals)
Comparison
Reverse-hybridization strip assay vs real-time PCR (qPCR) kit for APOE genotyping (rs429358 and rs7412)
Design
Methodological pilot study
Answers are grounded in this paper and cite their sources.
Caution advised against interchangeable use of these APOE assays in CHD; leaves open need for validated genotyping methods in research.
Commercial APOE genotyping platforms are widely used in cardiovascular genetic studies, but their performance in genetically understudied populations is rarely verified. This pilot study compared a reverse-hybridization strip assay and a real-time PCR (qPCR) kit for APOE genotyping (rs429358 and rs7412) in Libyan participants and examined how their calls disagreed. In a validation subset of 28 individuals, the strip assay gave no valid result in 5 (17.9%). Among the 23 samples valid on both platforms, genotype concordance was 8/23 (34.8%; 95% CI 18.8–55.1%) and Cohen’s κ was 0.19 (slight agreement). Single-SNP agreement was 65.2% for rs429358 and 60.9% for rs7412. The strip assay consistently reported more minor alleles than qPCR, but without a sequencing reference standard it is unknown which platform is correct. APOE genotype frequencies in Libyan patients with coronary heart disease could therefore not be reliably determined; strip-derived calls for 60 patients are provided only as unverified, exploratory data (Additional file 1). Sequencing confirmation should precede any larger APOE association study in this population.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: